Description

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer[1].—–C58H78N16O14—-[1]Luna-Gutiérrez M, et al. Preclinical evaluation of the theranostic 68 Ga/177 Lu-[DOTA-CXCR4-L] pair [C]//Trends in Radiopharmaceuticals (ISTR-2019). Proceedings of an International Symposium. Programme and Abstracts. 2020. —-1223.34—-O=C(N[C@H]1CC2=CC3=C(C=C2)C=CC=C3)[C@H](CCCNC(N)=N)NC([C@@H](CCCNC(C4=CN=C(C=C4)NNC(CN5CCN(CCN(CCN(CC5)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)N(C)C([C@@H](CC6=CC=C(O)C=C6)NC(CNC1=O)=O)=O)=O–Cancer–10 mM in DMSO–CXCR—-GPCR/G Protein;Immunology/Inflammation–Peptides